Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This research study aims to compare whether Phenylephrine 2.5% ophthalmic eye drop solution
can serve as a better indicator of the effect of a drooping upper eyelid (ptosis) by covering
part of the upper portion of the field of vision as compared to traditional use of tape to
lift up the upper eyelid in the evaluation of patients for surgical upper eyelid repair.
Phase
Phase 4
Funding Agency/Sponsor
Other
Disease
Other
Enrollment Eligibility
Inclusion Criteria:
- Individuals diagnosed with ptosis undergoing conjunctival Muller's muscle resection
evaluation.
- Individuals who can tolerate and have no hypersensitivity to phenylephrine 2.5%
ophthalmic solution.
- Individuals who can tolerate eye-drop medications.
- Individuals who are physically able to take a tangent screen visual field test.
- Age: Adults who can comprehend the instructions and procedures (18-90 years old).
Exclusion Criteria:
- This study will not incorporate any of the following at-risk populations: adults unable
to consent, individuals who are not yet adults, pregnant women, prisoners.
- This study will not include participants who refuse to consent.
- This study will not include participants who are too tired or unable to take a tangent
screen visual field test (see Risk to Subjects).
- This study will not include individuals who may not be able to tolerate phenylephrine
2.5% ophthalmic solution.
- Specifically, those with a past medical history of bradycardia, hypotension, autonomic
dysfunction, or severe cardiovascular disease
- This study will not include individuals who consume drugs contraindicated in
phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane
Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors